Skip to content
  1. Home
  2. Recovery & healing
  3. BPC-157

Recovery & healing

BPC-157

A 15-amino-acid fragment of the gastric body-protection compound, the most widely self-administered healing peptide for tendon, ligament, muscle, and gut injuries.

Research chemical Recovery & healing

Reviewed 2026-09-12
Full name
Body Protection Compound 157
Also known as
BPC-157 acetate, PL 14736, Bepecin, Pentadecapeptide BPC 157, Arg-BPC-157 (stable version)
Regulatory status
Research chemical / not FDA-approved. Tested in a handful of small human trials under the name PL 14736 (rectal enemas for ulcerative colitis); most other human use is off-label self-administration.

Origin

A fragment of a larger gastric-juice protein called Body Protection Compound. It occurs naturally in the human GI tract, and older Croatian tissue-distribution work found it expressed at low levels in lung, kidney, and skin too.

Mechanism

It doesn't bind classical receptors: dopamine, serotonin, histamine, adrenergic, muscarinic, and adenosine receptors have all been screened and show no affinity. Its effects instead run through upregulated growth-factor receptor expression (including growth hormone receptor in tendon fibroblasts), nitric-oxide modulation, and strong pro-angiogenic signaling. In animal models it consistently speeds fibroblast activity, blood vessel formation, and collagen organization at injury sites while suppressing scar tissue.

Research summary

Evidence

The published evidence base is large, over 200 papers, but almost entirely rodent and in-vitro. Repeated findings include faster healing of tendon, ligament, muscle, and nerve transections; faster healing of skin incisions, burns, and GI fistulas; protection against and healing of gastric ulcers; and a strong anti-inflammatory effect across multiple models. Human data is limited to Phase I/II trials of a rectal enema formulation (PL 14736) in healthy volunteers and ulcerative colitis patients in the early 2000s: well tolerated, with a statistically significant improvement in disease-activity scores versus placebo, and essentially no systemic absorption from the rectal route. No modern human dosing, efficacy, or long-term safety trials exist for the injectable or oral forms people use. One red flag: essentially every animal study on BPC-157 reports a positive result, which points to publication bias. Treat individual studies as suggestive, not proof. One in-vitro plasma-stability study found roughly 36% of BPC-157 still intact after 60 minutes, implying a plasma half-life in the range of 40 minutes — short, consistent with why community protocols favor frequent small doses over infrequent large ones.

Evidence tier: Research chemical — see the methodology note for how this is assessed.

Citations

Reported benefits

  • Faster recovery from tendon, ligament and muscle strains reported anecdotally and in animal studies
  • Reduced joint and connective-tissue pain in long-standing injuries
  • Improved gut symptoms (reflux, IBD-type symptoms, leaky-gut complaints) reported by oral users
  • General anti-inflammatory effect described by long-term users

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
RouteReported protocol
Subcutaneous injection (most commonly used for systemic/peripheral healing)A frequently cited compounding-pharmacy protocol is 300 mcg once daily for 30 days. A very common self-administered pattern in online communities is 250 mcg injected subcutaneously into belly fat, twice daily. Conservative starting point: 100 mcg once daily, increasing slowly while watching for reactions.
Oral (capsules or reconstituted drops)500 mcg, twice daily is a commonly reported oral dose. The 'stable' arginine-salt version (Arg-BPC-157) survives low stomach pH far better than the acetate salt and is generally preferred for oral use, though orally dosed BPC-157 is too large a molecule to be meaningfully absorbed intact — any systemic effect from oral dosing is unproven and the community consensus is that oral use is mainly reported to help local GI complaints, not peripheral joint or tendon injuries.
Local/near-injury injectionSome experienced users inject near (not into) an injury site on the theory of a local concentration effect; mainstream practice is simple subcutaneous injection into abdominal fat, which is easier, safer, and has the deepest anecdotal track record.

Side effects

  • Injection-site irritation, stinging, occasional bruising
  • Drowsiness / increased sleep need reported in the first 1-2 weeks by some users
  • Rare reports of headache or lightheadedness
  • No established maximum tolerated human dose; animal toxicology found no lethal dose up to very high doses, but this has not been replicated in modern controlled human trials

Safety notes

Safety: Legal status is grey-market in most countries: possessing the research chemical is typically not illegal, but it's sold 'not for human consumption' and falls outside any regulatory framework. No long-term human safety data exists for the doses and routes people use. People with active cancer should be cautious: BPC-157's strong pro-angiogenic activity is exactly what makes it good at healing tissue, and in theory could also feed a tumor's blood supply. This hasn't been directly studied.
Community & reddit notes (anecdotal — not clinical evidence)

One of the most discussed peptides in self-experimentation communities (notably r/Peptides), with unusually consistent reporting: people using injectable BPC-157 on stalled tendon, ligament, or joint injuries report it 'restarting' healing within days to a few weeks, often alongside noticeably increased sleepiness the first week. Users with connective tissue disorders (EDS/HSD) who stack it with GH secretagogues like CJC-1295/Ipamorelin report stronger, more durable results than BPC-157 alone. Oral users consistently report GI benefit but are far less confident about peripheral joint or tendon benefit; the community's strong prior is that injection is needed for systemic connective-tissue effects, while oral is a cheaper option purely for gut issues.

Used in stacks

Community combinations that include BPC-157 — see each stack page for the combination-specific rationale and evidence.

Mixing compatibility

Pulled from a community-charted mixing-compatibility reference (anecdotal, clinic-use, and community-reported signals) — not a safety guarantee. Verify independently before combining anything.

Used together in wellness-clinic protocols

Anecdotally combined (outside clinic protocols)

Reported as a combination to avoid